Lors de la pr\u00e9sentation des r\u00e9sultats du quatri\u00e8me trimestre de Jazz Pharmaceuticals, le PDG Bruce Cozadd a rapidement \u00e9voqu\u00e9 l’int\u00e9r\u00eat de l’entreprise pour les acquisitions. “Nous pr\u00e9voyons de diversifier davantage nos portefeuilles commercial et de d\u00e9veloppement gr\u00e2ce \u00e0 une strat\u00e9gie de d\u00e9veloppement d\u2019entreprise,” a-t-il d\u00e9clar\u00e9. “Nous examinons des actifs en neurosciences et en oncologie, ainsi que d’autres maladies rares,” a-t-il ajout\u00e9.<\/p>\n
Cozadd a \u00e9galement mentionn\u00e9 une bonne nouvelle pour Jazz concernant son produit phare, Epidiolex, utilis\u00e9 pour traiter certaines crises d’\u00e9pilepsie. La soci\u00e9t\u00e9 a conclu un accord avec les fabricants de g\u00e9n\u00e9riques, repoussant leur lancement \u00e0 la fin des ann\u00e9es 2030, selon Ren\u00e9e Gal\u00e1, pr\u00e9sidente de Jazz. Bien que Cozadd n’ait pas donn\u00e9 de d\u00e9tails, cela assure \u00e0 Jazz une source de revenus stable pour les ann\u00e9es \u00e0 venir, ce qui pourrait encourager d’autres acquisitions. Epidiolex, le seul produit \u00e0 base de CBD approuv\u00e9 par la FDA, devrait atteindre le statut de blockbuster cette ann\u00e9e avec des ventes de 972 millions de dollars en 2024.<\/p>\n
Jazz a acquis Epidiolex en rachetant GW Pharmaceuticals pour 7,2 milliards de dollars en 2021. Depuis, aucune autre acquisition majeure n’a \u00e9t\u00e9 r\u00e9alis\u00e9e, mais le directeur financier Philip Johnson a affirm\u00e9 que l’entreprise reste active dans ce domaine.<\/p>\n
Pour 2025, Jazz pr\u00e9voit des revenus totaux entre 4,15 et 4,4 milliards de dollars, soit une croissance de 5 % par rapport \u00e0 l’ann\u00e9e pr\u00e9c\u00e9dente. Gr\u00e2ce \u00e0 une r\u00e9duction de sa dette et \u00e0 des flux de tr\u00e9sorerie solides, Jazz dispose de ressources financi\u00e8res importantes pour de nouvelles acquisitions, selon Johnson.<\/p>\n
En plus d’Epidiolex, Jazz a acquis le m\u00e9dicament Ziihera, approuv\u00e9 pour le traitement du cancer des voies biliaires HER2-positif, via un accord potentiel de 1,76 milliard de dollars avec Zymeworks. Jazz estime que Ziihera pourrait g\u00e9n\u00e9rer plus de 2 milliards de dollars de ventes \u00e0 son apog\u00e9e.<\/p>\n
Jazz a report\u00e9 les r\u00e9sultats d\u2019une \u00e9tude de phase 3 pour Ziihera dans le cancer gastro-\u0153sophagien \u00e0 la fin de 2025, en raison de la progression plus lente des \u00e9v\u00e9nements tumoraux. Le m\u00e9dicament devra attendre pour p\u00e9n\u00e9trer des march\u00e9s plus vastes, comme le cancer du sein HER2-positif.<\/p>\n
Par ailleurs, Cozadd et le conseil d’administration cherchent un successeur, car il pr\u00e9voit de quitter son poste de PDG d’ici fin 2025, tout en restant pr\u00e9sident de l’entreprise. “Nous allons prendre notre temps pour trouver la bonne personne,” a-t-il d\u00e9clar\u00e9.<\/p>\n","protected":false},"excerpt":{"rendered":"
Lors de l’appel sur les r\u00e9sultats du quatri\u00e8me trimestre de Jazz Pharmaceuticals, le PDG Bruce Cozadd a rapidement attir\u00e9 l’attention des investisseurs sur l’int\u00e9r\u00eat de l’entreprise pour les acquisitions.<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[684],"tags":[],"class_list":["post-69592","post","type-post","status-publish","format-standard","hentry","category-nouvelles-pharmaceutiques"],"_links":{"self":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/69592","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/comments?post=69592"}],"version-history":[{"count":1,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/69592\/revisions"}],"predecessor-version":[{"id":69639,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/posts\/69592\/revisions\/69639"}],"wp:attachment":[{"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/media?parent=69592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/categories?post=69592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pharmacie-vezere.com\/promotions\/wp-json\/wp\/v2\/tags?post=69592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}